Core Viewpoint - The stock of Haishike experienced a decline of 2.20% on October 29, 2023, with a current price of 50.58 yuan per share, reflecting a total market capitalization of 566.45 billion yuan. Despite a year-to-date increase of 53.37%, the stock has seen a downward trend in recent trading days [1][2]. Financial Performance - For the period from January to September 2025, Haishike reported a revenue of 3.3 billion yuan, representing a year-on-year growth of 19.95%. However, the net profit attributable to shareholders decreased by 22.66% to 295 million yuan [2]. - Cumulatively, Haishike has distributed 3.673 billion yuan in dividends since its A-share listing, with 687 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 12.87% to 12,900, with an average of 37,342 circulating shares per shareholder, down by 11.40% from the previous period [2]. - The top ten circulating shareholders include various funds, with notable increases in holdings from several institutional investors, such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited [3]. Business Overview - Haishike, established on August 26, 2005, and listed on January 17, 2012, specializes in the research, development, production, and sales of chemical pharmaceuticals. The main revenue sources include anesthetic products (39.81%), cooperative product-related income (23.59%), and other therapeutic areas [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors such as hypertension treatment and innovative drugs [1].

Group 1 - The core point of the news is that Haikang Technology's stock price increased by 5.03%, reaching 51.78 CNY per share, with a total market capitalization of 57.989 billion CNY [1] - Haikang Technology was established on August 26, 2005, and went public on January 17, 2012. The company specializes in the research, development, production, and sales of chemical pharmaceuticals [1] - The main revenue composition of Haikang Technology includes: anesthetic products (39.81%), cooperative product-related income (23.59%), other indications (17.02%), parenteral nutrition (10.32%), antiemetics for tumors (8.15%), and other (supplement) (0.86%) [1] Group 2 - According to data, one fund under CITIC Jiankong holds a significant position in Haikang Technology, with 1 million shares, accounting for 3.63% of the fund's net value [2] - The CITIC Jiankong Medical Reform A fund (002408) has a total scale of 603 million CNY and has achieved a return of 26.89% this year, ranking 3036 out of 8161 in its category [2] - The fund manager, Xie Wei, has been in position for 7 years and 135 days, with the best fund return during his tenure being 90.48% [2]